An acute leukemia of ambiguous lineage in which there is a dual population of blasts with each population expressing markers of a distinct lineage (myeloid and lymphoid or B-and T-lymphocyte). (WHO, 2...
Comprehensive, easy-to-understand information about this condition
How we create this content →Documentation for bilineal acute myeloid leukemia is limited due to its rarity and the complexity of its clinical presentation. Because this condition affects a small number of individuals, systematic clinical studies are scarce. The lack of identified genes and inheritance patterns further complicates our understanding, making it challenging to gather comprehensive clinical data.
To navigate your diagnosis, consider seeking a hematologist with expertise in acute leukemias, particularly those familiar with bilineal presentations. Additionally, you may want to explore clinical trials as a treatment option. Resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov can provide valuable information. While no patient organizations are currently identified for this condition, participating in clinical trials can also help contribute to the understanding of bilineal acute myeloid leukemia.
There are several orphan drugs designated for bilineal acute myeloid leukemia, including Azacitidine and Gemtuzumab ozogamicin, among others. Additionally, there are currently 2 active clinical trials exploring potential treatments for this condition. For more information on these trials, you can visit ClinicalTrials.gov at https://clinicaltrials.gov/search?cond=bilineal%20acute%20myeloid%20leukemia.
Actionable guidance for navigating care for bilineal acute myeloid leukemia
To navigate your diagnosis, consider seeking a hematologist with expertise in acute leukemias, particularly those familiar with bilineal presentations. Additionally, you may want to explore clinical trials as a treatment option. Resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov can provide valuable information. While no patient organizations are currently identified for this condition, participating in clinical trials can also help contribute to the understanding of bilineal acute myeloid leukemia.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Documentation for bilineal acute myeloid leukemia is limited due to its rarity and the complexity of its clinical presentation. Because this condition affects a small number of individuals, systematic clinical studies are scarce. The lack of identified genes and inheritance patterns further complicates our understanding, making it challenging to gather comprehensive clinical data.
To navigate your diagnosis, consider seeking a hematologist with expertise in acute leukemias, particularly those familiar with bilineal presentations. Additionally, you may want to explore clinical trials as a treatment option. Resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov can provide valuable information. While no patient organizations are currently identified for this condition, participating in clinical trials can also help contribute to the understanding of bilineal acute myeloid leukemia.
There are several orphan drugs designated for bilineal acute myeloid leukemia, including Azacitidine and Gemtuzumab ozogamicin, among others. Additionally, there are currently 2 active clinical trials exploring potential treatments for this condition. For more information on these trials, you can visit ClinicalTrials.gov at https://clinicaltrials.gov/search?cond=bilineal%20acute%20myeloid%20leukemia.
Actionable guidance for navigating care for bilineal acute myeloid leukemia
To navigate your diagnosis, consider seeking a hematologist with expertise in acute leukemias, particularly those familiar with bilineal presentations. Additionally, you may want to explore clinical trials as a treatment option. Resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov can provide valuable information. While no patient organizations are currently identified for this condition, participating in clinical trials can also help contribute to the understanding of bilineal acute myeloid leukemia.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Documentation for bilineal acute myeloid leukemia is limited due to its rarity and the complexity of its clinical presentation. Because this condition affects a small number of individuals, systematic clinical studies are scarce. The lack of identified genes and inheritance patterns further complicates our understanding, making it challenging to gather comprehensive clinical data.
To navigate your diagnosis, consider seeking a hematologist with expertise in acute leukemias, particularly those familiar with bilineal presentations. Additionally, you may want to explore clinical trials as a treatment option. Resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov can provide valuable information. While no patient organizations are currently identified for this condition, participating in clinical trials can also help contribute to the understanding of bilineal acute myeloid leukemia.
There are several orphan drugs designated for bilineal acute myeloid leukemia, including Azacitidine and Gemtuzumab ozogamicin, among others. Additionally, there are currently 2 active clinical trials exploring potential treatments for this condition. For more information on these trials, you can visit ClinicalTrials.gov at https://clinicaltrials.gov/search?cond=bilineal%20acute%20myeloid%20leukemia.
Actionable guidance for navigating care for bilineal acute myeloid leukemia
To navigate your diagnosis, consider seeking a hematologist with expertise in acute leukemias, particularly those familiar with bilineal presentations. Additionally, you may want to explore clinical trials as a treatment option. Resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov can provide valuable information. While no patient organizations are currently identified for this condition, participating in clinical trials can also help contribute to the understanding of bilineal acute myeloid leukemia.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 30, 2026
Consider asking your healthcare providers these condition-specific questions
European rare disease database
AI-Generated Content: This summary was generated using AI. Content has been fact-checked. Always consult with qualified healthcare providers for medical guidance.
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.